Loading stock data…
CNTB
$2.12+0.02 (+0.95%)
Market ClosedLast close Jun 12
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Connect Biopharma Holdings Limited in the Healthcare sector is trading at $2.12 with a market capitalization of $140M. Wall Street consensus targets $7.07 (7 analysts), implying a +233.6% move over the next 12 months. The stock is currently 45% below its 52-week high of $3.82, remaining 8.6% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +233.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $169,000 | $0↓ | $16,000↓ | $48,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.61M↓ | -$15.53M↑ | -$17.68M↓ | -$13.42M↓ | -$11.45M |
| Net Income | -$19.40M↓ | -$15.11M↑ | -$17.20M↓ | -$12.90M↓ | -$10.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacer...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$140.41M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-151.58%
Volume
Today's trading volume
173,605
Recent News
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026
Connect Biopharma (NASDAQ:CNTB) Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study. Speaking during a fireside chat with H.C. Wainwright analyst
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses
Connect Biopharma (NASDAQ:CNTB) shared new clinical and preclinical updates on rademikibart, its IL-4 receptor alpha monoclonal antibody, highlighting preliminary top-line results from an intravenous (IV) clinical pharmacology study in asthma and COPD and presenting phase III atopic dermatitis data
Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts
Connect Biopharma (NASDAQ:CNTB) CEO Barry Quart outlined the company’s focus on rademikibart, an IL-4 receptor alpha monoclonal antibody he described as a “next-generation DUPIXENT,” during a presentation at the Leerink Partners Global Healthcare Conference. Quart emphasized both chronic and acute-c
Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference
Connect Biopharma (NASDAQ:CNTB) CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it described as a novel treatment approach for acute exacerbations of asthma and chronic obstructive pu